GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SciSparc Ltd
SciSparc is an Israeli pharmaceutical company specializing in cannabinoid-based drugs for the treatment of neurological disorders. Its stock price is a bet on the medical potential of these compounds and the success of its clinical programs.
Share prices of companies in the market segment - Pharma psycho
SciSparc is an Israeli pharmaceutical company developing cannabinoid-based drugs for the treatment of central nervous system disorders. We've categorized it as a "Pharma: Psycho" stock. The chart below shows how investors view this risky but promising biotech sector.
Broad Market Index - GURU.Markets
SciSparc is an Israeli pharmaceutical company developing cannabinoid-based drugs for the treatment of central nervous system disorders. It is a component of the GURU.Markets index. The chart below shows the US market. See how its stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
SPRC - Daily change in the company's share price SciSparc Ltd
SciSparc Ltd.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its cannabinoid-based drugs.
Daily change in the price of a set of shares in a market segment - Pharma psycho
SciSparc Ltd. is a pharmaceutical company specializing in cannabinoid-based medications for the treatment of central nervous system disorders. This is a speculative sector. The chart below illustrates the high volatility typical of this niche, reflecting its risks and potential.
Daily change in the price of a broad market stock, index - GURU.Markets
SciSparc is an Israeli biotech company developing cannabinoid-based drugs. The company operates at the intersection of two volatile sectors: biotech and cannabis. Its shares respond to scientific and regulatory news, adding unique dynamics to the market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SciSparc Ltd
For SciSparc Ltd., year-over-year performance tells the story of its diversified development portfolio. Its 12-month market cap change reflects progress in its programs, from Tourette's syndrome treatment to pain management, as well as its strategic investments in other biotech companies, creating a complex picture for investors.
Annual dynamics of market capitalization of the market segment - Pharma psycho
SciSparc, an Israeli biotech company, develops drugs for the treatment of central nervous system diseases. Its performance is completely independent of the sector and depends on news about clinical trials. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
SciSparc, a biotech company working with cannabinoids, is showing momentum in its clinical trials. Its performance, compared to the market, is a purely speculative bet that its drugs for treating CNS diseases will prove effective and safe.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SciSparc Ltd
SciSparc is an Israeli biopharmaceutical company. Its monthly performance is entirely dependent on progress in its clinical programs, often related to cannabinoids. News of trial results is the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Biotechnology using cannabinoids to treat neurological disorders is a science-intensive approach to cannabis. The dynamics of this sector, shown in the chart, reflect its speculative nature. Companies like SciSparc are conducting research in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
SciSparc Ltd. is an Israeli pharmaceutical company specializing in drugs for the treatment of central nervous system disorders. Its shares move in sync with clinical trial news. The company's performance is uncorrelated with the market and represents a high-risk bet on the success of its innovative approach to medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SciSparc Ltd
Shares of SciSparc, an Israeli pharmaceutical company developing cannabinoid-based drugs, are extremely volatile. Weekly price movements are entirely dependent on news about clinical trials in neuroscience. The chart below illustrates how short-term scientific developments and investor expectations in this niche shape the stock's value.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
SciSparc is developing cannabinoid-based drugs for the treatment of neurological disorders. This is a promising, but legally and scientifically complex, area. The chart clearly demonstrates how regulatory news and research results create their own highly volatile trend for the company's stock.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
SciSparc is a biopharmaceutical company focused on cannabinoids. This chart shows how its weekly performance is independent of the broader market. Its stock price movements are driven solely by clinical trial progress and regulatory decisions, not by the S&P 500.
Market capitalization of the company, segment and market as a whole
SPRC - Market capitalization of the company SciSparc Ltd
SciSparc Ltd.'s price chart reflects its research into treating central nervous system diseases using cannabinoids. This Israeli biotech company's market cap depends on the success of its clinical programs. Its dynamics illustrate the high volatility and speculative interest in this area of medicine.
SPRC - Share of the company's market capitalization SciSparc Ltd within the market segment - Pharma psycho
SciSparc's market share in psychopharmacology reflects its focus on developing cannabinoid-based drugs for the treatment of central nervous system disorders. Its market share reflects its scientific approach to drug development for conditions such as Tourette syndrome and autism.
Market capitalization of the market segment - Pharma psycho
The chart illustrates the total value of biotech companies developing cannabinoid-based drugs. SciSparc is one such player. The chart's dynamics reflect the high volatility and speculative interest in the sector, which is attempting to transform cannabis into evidence-based medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of pharmaceuticals targeting the central nervous system. SciSparc's market capitalization is based on its developments in treating conditions such as Tourette syndrome and autism. The line shows how a small company is fighting for its share in one of the most complex areas of medicine.
Book value capitalization of the company, segment and market as a whole
SPRC - Book value capitalization of the company SciSparc Ltd
SciSparc Ltd.'s book value represents its scientific capital. The chart below reflects the valuation of its patent portfolio and developments in cannabinoid-based treatments for central nervous system diseases. The line's growth signals progress in clinical research, which is the company's primary asset.
SPRC - Share of the company's book capitalization SciSparc Ltd within the market segment - Pharma psycho
For SciSparc, which develops cannabinoid-based drugs for the central nervous system, its tangible assets are its laboratories and R&D infrastructure. The chart shows its share of this scientific base, which forms the foundation for the creation of new treatments for neurological and psychiatric disorders.
Market segment balance sheet capitalization - Pharma psycho
Biotechnology is a world of contrasts. The graph shows the massive factories of pharmaceutical giants. SciSparc, as a development company, has a more streamlined model. Its value lies in its intellectual property rights to drugs for treating central nervous system diseases, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
SciSparc develops cannabinoid-based medications for the treatment of central nervous system disorders. The company's assets are not plantations, but a patent portfolio and clinical trial data. The chart shows the resources devoted to studying the therapeutic potential of these substances.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SciSparc Ltd
SciSparc is an Israeli pharmaceutical company specializing in drugs that target the endocannabinoid system. Its market capitalization is based on its research portfolio and its developments in the treatment of neurological disorders.
Market to book capitalization ratio in a market segment - Pharma psycho
SciSparc Ltd. is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Its value depends on the success of clinical trials. This chart shows how market valuation is a bet on the future.
Market to book capitalization ratio for the market as a whole
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. The company's market valuation, shown on the chart, reflects investors' faith in its scientific research and patent portfolio, rather than its tangible assets.
Debts of the company, segment and market as a whole
SPRC - Company debts SciSparc Ltd
SciSparc, a pharmaceutical company specializing in central nervous system diseases, is leveraging its financial structure to conduct clinical trials. This chart shows how the company is investing in the development of its cannabinoid-based drugs for conditions such as Tourette syndrome and autism.
Market segment debts - Pharma psycho
SciSparc is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart shows how its leverage reflects the risky nature of its research and the need for funding to conduct clinical trials in this complex and regulatory-sensitive area.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SciSparc Ltd
Ucommune International is one of the largest coworking space operators in China. This business requires significant investments in leasing and furnishing office space. This chart shows the high debt load typical for the industry, and its dynamics reflect the company's ability to manage its liabilities in the face of fluctuating demand.
Market segment debt to market segment book capitalization - Pharma psycho
SciSparc is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart compares its debt to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its clinical research in this complex and regulatory-sensitive field.
Debt to book value of all companies in the market
SciSparc Ltd. is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This is an innovative but risky field. This chart of total market debt provides an indication of the availability of capital to fund SciSparc's clinical programs in this complex therapeutic niche.
P/E of the company, segment and market as a whole
P/E - SciSparc Ltd
This chart shows the valuation of SciSparc, an Israeli pharmaceutical company focused on psychoactive substances. P/E ratios are not applicable here. The company's valuation is a bet that its drugs, possibly cannabinoid-based, will be effective in treating central nervous system disorders.
P/E of the market segment - Pharma psycho
SciSparc is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders such as Tourette syndrome and Alzheimer's disease. This chart shows the average valuation for the psychopharmaceuticals sector, reflecting investor interest in the therapeutic potential of cannabinoids.
P/E of the market as a whole
SciSparc Ltd. is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders such as Tourette syndrome and autism. This risk appetite chart helps understand how investors evaluate biotech companies operating in a complex and regulated field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SciSparc Ltd
SciSparc is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart reflects market expectations for the success of its clinical programs. Future revenue depends on trial results and regulatory approval.
%20P%2FE%20SciSparc%20Ltd&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SciSparc-Ltd&v=1772666127170 "Chart of the company's future (projected) P/E SciSparc Ltd")
Future (projected) P/E of the market segment - Pharma psycho
SciSparc is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart reflects speculative market expectations. It shows how investors view its scientific research and drug approval chances compared to other companies in this niche.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772666127172 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
SciSparc Ltd is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials. The overall market optimism, as demonstrated by this chart, is important for attracting the capital needed to conduct lengthy and expensive research in this complex area.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772666127176 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SciSparc Ltd
SciSparc is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Its financial activities are focused on clinical research. This chart reflects the significant R&D investments necessary to prove the safety and efficacy of its therapeutic candidates.
Profit of companies in the market segment - Pharma psycho
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This graph, showing overall sector profitability, reflects the medical potential of cannabis. SciSparc's success in clinical trials could lead to new treatments and impact the entire industry.
Overall market profit
SciSparc is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This is a complex and highly regulated field. Its future depends on the results of clinical trials and changing regulatory attitudes toward the medical use of cannabis.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SciSparc Ltd
SciSparc is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Future revenue projections presented here are speculative and depend on the success of clinical trials. Analysts are evaluating the potential of its developments in neurology and psychiatry.
%20profit%20of%20the%20company%20SciSparc%20Ltd&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SciSparc-Ltd&v=1772666127241 "Graph of future (projected) profit of the company SciSparc Ltd")
Future (predicted) profit of companies in the market segment - Pharma psycho
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart shows revenue projections for the psychopharmacology segment. It helps assess how the company's scientific approach to cannabis compares to overall trends in the treatment of neurological disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772666127267 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
SciSparc develops cannabinoid-based drugs for the treatment of central nervous system disorders. As with many biotech companies, this chart is important for SciSparc as an indicator of the investment climate. Positive economic expectations facilitate raising the funding needed to conduct clinical trials and bring products to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772666127278 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SciSparc Ltd
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart, plotting market capitalization against minimum revenue, is an indicator of expectations. It shows how investors view its scientific portfolio and potential in the medical cannabis market.
P/S market segment - Pharma psycho
SciSparc Ltd is a pharmaceutical company specializing in the development of cannabinoid-based treatments for central nervous system disorders. The company targets conditions such as Tourette syndrome and autism. This chart shows how investors value the psychopharmacology sector, demonstrating the level of confidence in SciSparc's scientific approach and development pipeline.
P/S of the market as a whole
SciSparc Ltd. is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart, reflecting average valuations, shows how investors view the risky but potentially disruptive biotech sector against the broader economy.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SciSparc Ltd
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart shows the market's estimate of its potential future revenue. It reflects investor confidence in the success of its clinical programs and the commercial potential of its innovative therapies.
%20P%2FS%20SciSparc%20Ltd&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SciSparc-Ltd&v=1772666127298 "The graph of the company's future (projected) P/S SciSparc Ltd")
Future (projected) P/S of the market segment - Pharma psycho
SciSparc is an Israeli biopharmaceutical company developing cannabinoid-based drugs for the treatment of central nervous system disorders. The chart shows the average estimated future revenue in the psychopharmacology sector. It helps understand how investors view SciSparc's scientific platform and its prospects in this complex and high-risk field.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772666127304 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
SciSparc (SPRC) is a pharmaceutical company developing cannabinoid-based drugs for the treatment of neurological disorders. Their future depends on the results of clinical trials and regulatory approvals. This graph of general economic expectations is irrelevant for a company operating in a highly specialized medical field.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772666127319 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SciSparc Ltd
SciSparc is a pharmaceutical company specializing in diseases of the central nervous system. Being in the clinical stage, it has no sales revenue. Its financial history consists of investments in the development of drugs for conditions such as Tourette syndrome. The graph will reflect future revenue from licensing or sales.
Sales of companies in the market segment - Pharma psycho
SciSparc Ltd. is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. While in the clinical stage, it has no revenue yet, but its future success depends on its innovative approaches to treating conditions such as Tourette syndrome.
Overall market sales
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials. The overall economic situation, shown in this chart, influences the investment climate in the biotech sector and the availability of funding for R&D in this specific niche.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SciSparc Ltd
SciSparc is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Its future revenue depends on the success of clinical trials. This chart reflects analysts' long-term forecasts for the potential of its developments in neurology and psychiatry.
%20sales%20of%20the%20company%20SciSparc%20Ltd&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SciSparc-Ltd&v=1772666127359 "Schedule of future (projected) sales of the company SciSparc Ltd")
Future (projected) sales of companies in the market segment - Pharma psycho
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart shows the outlook for the psychopharmaceutical sector. It reflects the growing interest in the therapeutic potential of cannabinoids, which underpins SciSparc's research.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772666127363 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, is important to SciSparc. The company develops cannabinoid-based drugs for the treatment of central nervous system disorders. Funding for its research depends on capital inflows, which correlate with overall economic expectations.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772666127377 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SciSparc Ltd
SciSparc develops cannabinoid-based drugs for the treatment of central nervous system disorders. This chart shows the biotech company's financial performance at the clinical trial stage. Profitability is a long-term goal and depends on success in treating conditions such as Tourette syndrome and autism.
Market segment marginality - Pharma psycho
SciSparc is an Israeli pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. Profitability depends on the success of its clinical trial programs. This chart shows the average profitability in the pharmaceutical industry and provides context for assessing the potential of SciSparc's developments.
Market marginality as a whole
SciSparc is a pharmaceutical company specializing in developing cannabinoid-based therapies for central nervous system disorders. Its future depends on the success of clinical trials. This chart reflects the overall investment climate, which is critical for attracting capital for research in such a complex and highly regulated field.
Employees in the company, segment and market as a whole
Number of employees in the company SciSparc Ltd
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This graph reflects its compact scientific team. A small staff is typical for companies focused on R&D and clinical trials, where expertise, not numbers, is key.
Share of the company's employees SciSparc Ltd within the market segment - Pharma psycho
SciSparc develops cannabinoid-based drugs for the treatment of central nervous system disorders such as Tourette syndrome and autism. This chart shows the company's share of the total number of researchers in this narrow and complex field. This reflects its scientific potential and focus on solving problems for which there are few effective treatments.
Number of employees in the market segment - Pharma psycho
SciSparc Ltd. is a pharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders. This chart showing employment in psychopharmaceuticals is important. The growing number of neuroscientists working with cannabinoids indicates growing scientific interest in their therapeutic potential.
Number of employees in the market as a whole
SciSparc develops cannabinoid-based drugs for the treatment of central nervous system disorders. Their research requires significant capital investment. This graph of total employment reflects the investment climate. During periods of economic growth, as shown here, investors are more inclined to fund biotech companies working in new and promising areas.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SciSparc Ltd (SPRC)
SciSparc Ltd. is an Israeli pharmaceutical company specializing in drugs for the treatment of central nervous system disorders, including those using cannabinoids. It is another example of a biotech company with a very high market capitalization per employee. Its market capitalization reflects not current sales, but solely the potential of its neuroscience developments and patents.
%20of%20the%20company%20SciSparc%20Ltd%20(SPRC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SciSparc-Ltd-SPRC&v=1772666127416 "Chart of market capitalization per employee (in thousands of dollars) of the company SciSparc Ltd (SPRC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
SciSparc Ltd. is a pharmaceutical company specializing in the treatment of central nervous system disorders. Its market capitalization is based on its development pipeline and clinical trial results. This chart helps understand how investors value the intellectual capital generated by a small team of scientists compared to large pharmaceutical companies with their massive staffs.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772666127430 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
SciSparc develops cannabinoid-based drugs for the treatment of central nervous system disorders. It is a niche pharmaceutical company. This chart shows how the market views its research portfolio, where a small team of researchers is working to develop new treatments in a complex and highly regulated field.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772666127454 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SciSparc Ltd (SPRC)
SciSparc is an Israeli pharmaceutical company specializing in the treatment of central nervous system (CNS) disorders, including Tourette syndrome and autism, often using cannabinoids. This chart reflects their R&D status: it shows how much the company spends (negative profit) on each scientist to conduct clinical trials of these complex drugs.
%20Chart%20SciSparc%20Ltd%20(SPRC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SciSparc-Ltd-SPRC&v=1772666127464 "Company Profit Per Employee (in thousands of dollars) Chart SciSparc Ltd (SPRC)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
SciSparc Ltd. specializes in developing cannabinoid-based drugs for the treatment of neurological disorders. For a pharmaceutical company focused on research, this chart reflects the effectiveness of project and capital management. Positive performance in this indicator will be driven by successful clinical trials and partnerships with major pharmaceutical companies.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772666127474 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
SciSparc (SPRC) is an Israeli biopharmaceutical company specializing in the development of cannabinoid-based drugs for the treatment of neurological disorders (such as Tourette syndrome). This is an R&D business. This indicator is negative and reflects the investment in scientific personnel working in the narrow niche of cannabis-based pharmaceuticals.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772666127482 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SciSparc Ltd (SPRC)
SciSparc Ltd. is a pharmaceutical company specializing in cannabinoid-based drugs for the treatment of central nervous system disorders. This graph shows minimal revenue during the research phase. It is important as a basis for assessing the future commercial success of their developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SciSparc-Ltd-SPRC&v=1772666127485 "Sales chart per company employee SciSparc Ltd (SPRC)")
Sales per employee in the market segment - Pharma psycho
SciSparc is an Israeli pharmaceutical company developing cannabinoid-based drugs for the treatment of central nervous system disorders (e.g., Tourette syndrome, autism). This is an R&D business. This chart shows that the company has no commercial revenue. The productivity of their research team lies in advancing candidates through clinical trials.
Sales per employee for the market as a whole
EVgo (EVGO) builds and operates a nationwide network of fast charging stations for electric vehicles. This chart shows the efficiency of this infrastructure. An increase in this indicator means their stations are used more frequently, generating more revenue from electricity sales, while maintaining a compact operating staff.
Short shares by company, segment and market as a whole
Shares shorted by company SciSparc Ltd (SPRC)
SciSparc (SPRC) is an Israeli company developing cannabinoid- and psychedelic-based drugs. This chart shows the number of bearish bets. The shorts reflect the high regulatory hurdle and skepticism that these compounds will be approved for widespread medical use.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SciSparc-Ltd-SPRC&v=1772666127518 "Short Shares Chart for the Company SciSparc Ltd (SPRC)")
Shares shorted by market segment - Pharma psycho
SciSparc (SPRC) is an Israeli biotech company developing cannabinoid-based drugs for the treatment of central nervous system disorders (Tourette's, autism). The chart below shows the overall short position in the biotech sector. It demonstrates how skeptical investors are about medical cannabis and its regulatory prospects.
Shares shorted by the overall market
SciSparc is an Israeli biotech company specializing in cannabinoid-based drugs for the treatment of central nervous system disorders (such as Tourette's syndrome). This chart measures overall fear. When investors are fearful, they avoid stocks with triple risk: scientific (failure), regulatory (cannabis), and geopolitical (Israel). SPRC becomes an easy target for sell-offs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SciSparc Ltd (SPRC)
This chart for SciSparc is a barometer of speculation in cannabis biotech. The company is developing cannabinoid-based drugs for treatments (Tourette's syndrome, pain). "Overheating" (above 70) occurs due to positive early data. Regulatory barriers for cannabis and clinical setbacks (as was the case with COVID) lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SciSparc-Ltd-SPRC&v=1772666127531 "RSI 14 indicator chart for the company's stock SciSparc Ltd (SPRC)")
RSI 14 Market Segment - Pharma psycho
SciSparc is an Israeli biopharmaceutical company specializing in the treatment of central nervous system disorders. They use their technologies to enhance the effects of cannabinoids in the treatment of Tourette syndrome and autism. This chart reflects the overall sentiment in the psychopharmacology sector, helping to assess how the market views this speculative field.
RSI 14 for the overall market
SciSparc (SPRC) is a pharmaceutical company specializing in central nervous system drugs. Its success depends on clinical trials. This chart shows the overall market temperature. When the market is overheated (euphoric), investors are more willing to fund biotech, even in the early stages. During periods of panic (oversold), funding becomes expensive, which is a risk for companies like SPRC.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SPRC (SciSparc Ltd)
SciSparc (SPRC) is an Israeli pharmaceutical company developing cannabinoid-based therapies for the treatment of central nervous system disorders (such as Tourette's syndrome). This chart shows the average price target from analysts, reflecting their collective assessment of the risks and potential of its clinical pipeline in this complex area.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SPRC-SciSparc-Ltd&v=1772666127591 "A chart showing analyst consensus forecasts for the expected stock price. SPRC (SciSparc Ltd)")
The difference between the consensus estimate and the actual stock price SPRC (SciSparc Ltd)
SciSparc (SPRC) is an Israeli biotech company specializing in the development of cannabinoid-based drugs for the treatment of central nervous system disorders (Tourette's, Alzheimer's). This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in this unconventional R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SPRC-SciSparc-Ltd&v=1772666127632 "A chart showing the difference between the consensus forecast and the actual stock price. SPRC (SciSparc Ltd)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
SciSparc is an Israeli biotech company developing cannabinoid-based drugs for the treatment of neurological disorders (Tourette syndrome, autism). This chart shows general expectations for the psychopharma sector. It reflects whether experts believe in medical cannabis or consider the sector too risky.
Analysts' consensus forecast for the overall market share price
SciSparc (SPRC) is an Israeli biopharmaceutical company focused on treating CNS diseases. They are developing drugs based on cannabinoids and psychedelics. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, yet regulatoryly complex and speculative, areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SciSparc Ltd
SciSparc is an Israeli biotech company trying to harness cannabinoids. Their R&D pipeline uses derivatives (like Palmitoylethanolamide) to treat complex CNS disorders, such as Tourette's syndrome and autism. This chart is a pure R&D barometer. It doesn't reflect sales, but rather a speculative assessment of their clinical data, their patent portfolio, and their chances of success.
AKIMA Market Segment Index - Pharma psycho
SciSparc is an Israeli biopharmaceutical company focused on CNS (psycho) disorders. They are developing new treatments, including those using cannabinoids. This chart allows you to assess their position in the sector by comparing their composite index to the industry average, and understand whether they stand out from the crowd.
The AKIM Index for the overall market
SciSparc is a pharmaceutical company developing cannabinoid-based treatments for central nervous system disorders (Tourette syndrome, autism). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific development in a niche segment compares to overall economic trends.
